Kymera Therapeutics stock gains after Morgan Stanley conference highlights oral degrader pipeline

Published on 09/17/2026 at 18:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kymera Therapeutics stock has risen strongly over the past year, reaching around USD 119 on September 17, 2026 amid optimism over its oral degrader programs. Second quarter 2026 results showed a narrower loss per share and continued investment in late-stage studies.

KYMR, US50153V1061, Illustration mit AI erstellt.

Kymera Therapeutics stock (ISIN US50153V1061) is trading near USD 119 on the Nasdaq as of September 17, 2026, supported by strong gains over the past 12 months and fresh investor attention on its targeted protein degradation pipeline following a presentation at the Morgan Stanley Global Healthcare Conference on September 15, 2026.

Morgan Stanley conference puts oral degraders in focus

According to Investing.com, Kymera Therapeutics used its appearance at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026 to highlight how targeted protein degradation via oral degraders could expand treatment options in immuno-inflammatory diseases.

The same report notes that over the last twelve months the shares have climbed 142% to around USD 114.63, corresponding to a market capitalization of about USD 9.5 billion as of mid-September 2026, underscoring how strongly investors have re-rated the company in anticipation of key trial readouts.Investing.com

Upcoming data milestones and Q2 2026 results

As summarized by Investing.com, Kymera expects key results for its oral degrader candidates KT-579 and KT-621 by the end of 2024, with asthma data from the BREADTH study planned for 2027, while additional Phase I data for KT-579 in healthy volunteers and BROADEN2 data for KT-621 are also targeted for late 2024.

The same conference coverage explains that these results are intended to support the design of a Phase III program in atopic dermatitis in 2025, marking a potential transition toward late-stage development and creating clear clinical catalysts over the next roughly 12 to 24 months.Investing.com

In addition to the conference narrative, Kymera’s second quarter 2026 financial report showed a per-share loss of USD 0.62, slightly better than the Zacks Consensus Estimate of a USD 0.64 loss per share, illustrating modest outperformance versus expectations while the company continues to fund its development pipeline.Zacks

Valuation, volatility and analyst sentiment

Conference commentary cited by Investing.com points out that with a recent price around USD 114.63 and market capitalization of USD 9.5 billion, the stock appears expensive versus some fair value estimates, reflecting strong optimism about the commercial potential of Kymera’s pipeline.

The same analysis notes that Wall Street analysts remain positive with published price targets ranging between USD 111 and USD 180 as of mid-September 2026, indicating that even after a 142% twelve-month gain, many forecasts still see room for further upside if the late-stage data deliver.Investing.com

However, investors also need to weigh the risks: the same source highlights a beta of 1.96, signaling substantially higher share-price volatility than the overall market and underlining how strongly Kymera Therapeutics stock can react to clinical trial news or shifts in sentiment on high-growth biotechnology names.Investing.com

Kymera Therapeutics stock price and key market data

Per recent Nasdaq-based quote data summarized on a financial portal, Kymera Therapeutics stock last traded around USD 119 to USD 120 on the Nasdaq on September 17, 2026, up about 2% to 3% on the day, with a market capitalization in the region of USD 9.8 billion and reflecting its strong run over the past year.Yahoo Finance